Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. by Mórocz, I. A. et al.
Br. J. Cancer (1994). 70, 854) 856 © Macmillan Press Ltd.. 1994
Autocrine stimulation of a human lung mesothelioma cell line is mediated
through the transforming growth factor a/epidermal growth factor
receptor mitogenic pathway
I.A. Morocz, D. Schmitter, B. Lauber & R.A. Stahel
Division ofOncologi. Department ofMedicine, University Hospital CH-8091 Zurich, Switzerland.
Summarn Malignant cells frequently acquire a certain independency of exogenous growth factors via the
coexpression of epidermal growth factor receptor (EGFR) and epidermal growth factor (EGF)-related
molecules. In the present study we investigate a possible involvement of EGF-related molecules in the growth
of human lung mesothelioma. Four well-characterised cell lines are analysed for their responsiveness to
exogenous EGF and transforming growth factor m (TGF-a) as well as for coexpression of EGFR and
EGF TGF-m. Both growth factors are able to stimulate DNA synthesis in three cell lines, although the degree
of responsiveness is very variable, but neither EGF nor TGF-x has an effect on the cell line ZL34. In contrast.
no heterogeneity is observed in the expression of EGFR, which is similarly high in all cell lines. Analysis of
cell supernatants reveals that. whereas no EGF is detected. TGF-c is released by two cell lines. Furthermore.
these two cell lines. ZL5 and ZL34. are shown to express the membrane anchored precursor pro-TGF-m. Thus.
coexpression of EGFR and TGF-x is observed on two mesothelioma cell lines. The potential autocrine
mitogenic role of TGF-4 in these two cell lines was tested using neutralising antibodies against TGF- c and
EGFR. In ZL5 cells DNA synthesis was not affected by the presence of neutralising antibodies, indicating that
an external autocrine mitogenic pathway is not active in these cells. In ZL34 cells, however, the potential
autocrine loop could be disrupted, as DNA synthesis was significantly reduced in the presence of neutralising
antibodies. This result gives strong evidence for an autocrine role of TGF-u in the growth of the mesothelioma
cell line ZL34.
Autonomous proliferation of malignant cells in culture is a
frequently observed feature. This capacity may occur as a
result of autocnine secretion of growth factors, circumventing
the need for exogenous growth stimulatory signals. Prolifera-
tion in the absence of exogenous peptide growth factors,
coexpression of growth factor and its receptor and inhibition
of autonomous proliferation in the presence of specific
neutralising antibody to the putative growth factor or its
receptor are typical attributes of such cell lines. Since the
statement of the autocrine hypothesis (Sporn & Todaro.
1980). the existence of these autocrine loops have been
described for several different growth factors secreted by
carcinoma derived cell lines (Sporn & Roberts, 1992; Pusztai
et al.. 1993).
Mesothelioma. the tumour derived from mesothelial cells.
is mainly associated with exposure to asbestos fibres, as well
as to other natural or man-made carcinogenic fibres (Barrett
et al., 1989: Merchant, 1990). In vitro experiments using
mesothelial cells and mesothelioma cell lines allow the study
of growth conditions and mechanisms of these cells. For the
culturing of human mesothelial cells, epidermal growth factor
(EGF) is an essential element of the culture medium (La-
Rocca & Rheinwald, 1985; Lechner et al., 1989). EGF may
facilitate the establishment of human mesothelioma cell lines.
but it is not required for long-term culture (Versnel et al.,
1989). Among a large panel of defined growth factors tested,
EGF has been described to exhibit a mitogenic activity on
human mesothelioma cell lines (Lauber et al., 1992, 1993).
The EGF family comprises a growing number of molecules
related to EGF by amino acid sequence homology and or
structural similarity (Davis. 1990). Transforming growth fac-
tor a (TGF-a ) is a member of this family (Derynck. 1988).
The mature TGF-a molecule (50 amino acids) is released bx
proteolytic cleavage (Cappelluti et al.. 1993) from the pre-
cursor pro-TGF-a (160 amino acids). which is anchored in
the cell membrane. There is increasing evidence that TGF-m
plays an important role in the proliferation control of normal
and neoplastic tissues (Lee et al.. 1992). TGF-x has been
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shown to bind to the EGF receptor (EGFR) in order to
stimulate the proliferation of various carcinoma cell lines
(Massague, 1990). For autocrine activity coexpression of
TGF-a and EGFR is required, a pattern observed in numerous
tumour tissues and tumour-derived cell lines, e.g. co-
expression of TGF-x and EGF was found in 38% of non-
small-cell lung cancers (Rusch et al., 1993).
We have shown in our previous studies that EGF has a
mitogenic potential on mesothelioma cell lines (Lauber et al.,
1992, 1993). Several reports indicate that 50-80% of meso-
thelioma samples bear EGFR (Dazzi et al., 1990; Kayser et
al., 1990; Ramael et al., 1991). Considering these facts, we
aimed to elucidate the possible autocrine role of the EGF
TGF-a -EGFR route in four human lung mesothelioma cell
lines.
Materals and methods
Cell cultures and media conditioning
The pleural mesothelioma cell lines ZL5, ZL34, ZL55 and
SPC212 were established from previously untreated patients
as previously described (Schmitter et al., 1992). Cells were
routinely cultured in RPMI-1640 medium (Gibco Laborator-
ies, Glasgow, UK) supplemented with 2 mM glutamine (Flow
Laboratories, Irvine, UK) and 10% FCS (PAA, Linz, Austria)
at 37°C in a humidified atmosphere with 5% carbon dioxide.
For production of conditioned media, subconfluent cells
were washed twice with PBS and further cultured over 5 days
in protein-free RPMI-1640 medium alone as described pre-
viously (Lauber et al., 1992). Supernatants were spun at
700g for 15min and stored at -80'C.
[3H]thymidine incorporation assays
The mitogenic activity of growth factors and control media
was determined by a [3H]thymidine incorporation assay as
described in detail elsewhere (Lauber et al., 1992). Briefly,
cells were grown in RPMI-1640 10% FCS medium for 2-3
days in 75cm' culture flasks, washed twice with PBS and
incubated in protein-free RPMI-1640 medium for 24 h. These
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serum-depleted cells were then detached using trypsin 0.05%
EDTA 0.02% (Seromed, Berlin. Germany) and further cul-
tured in 96-well plates (2.000 cells per well) in RPMI-1640
medium alone for additional 24 h prior to the addition of test
substances; 24 h after the addition of the test substances.
[H]thymidine (1 gCi per well) was added as a 4 h pulse.
Mitogenic activity was determined by comparison with the
treatment of the cells with RPMI-1640 medium alone. defin-
ed as a mitogenic activity of 1.
Recombinant human EGF was purchased from Genzyme
(Cambridge. MA. USA) and recombinant human TGF-a
from Gibco (Gaithersburg. MD. USA).
Neutralisation assays
Neutralisation assavs were performed using two specific
mouse monoclonal antibodies (Abs) of the IgGI subclass: (i)
the anti-human EGFR Ab (Genzyme no. 1209-00. Cam-
bridge. MA. USA). recognising the extracellular domain of
the EGFR and inhibiting the binding of the ligand to the
receptor. and (ii) the anti-human TGF-a Ab (Ab-3. Onco-
gene Science no. GF15. Uniondale. NY. USA). interacting
with residues 34-50 of TGF-a . Both antibodies exert their
neutralising effect by spacial disruption of the pathway. The
mouse monoclonal IgGl antibody MOPC21 (Sigma no. M-
9269) was used as a non-specific control. The mouse mono-
clonal antibody against EGFR (Pierce no. 36154X. Rock-
ford. IL. USA) and the rabbit polyclonal anti-pro TGF-a Ab
directed against the intracellular domain of pro-TGF-a (a gift
from Dr Joan Massague. Memorial Sloan-Kettering Cancer
Center. New York. NY. USA) were used as non-neutralising
control antibodies.
Serum-depleted cells were prepared as described above.
and non-confluent cells (2.000 cells per well) were treated
with antibodies in a concentration range from 10-' to 10-9 Mi
(1:100 to 1:2.500 dilution factor for the polyclonal anti-
serum). A 4 h pulse of [3H]thymidine incorporation (1LCi
per well) was measured 24 h after treatment.
All experiments were performed in quadruplicates and re-
peated at least twice. Statistical analysis was performed by
Student's t-test.
Flows crtometrr
For FACScan analysis cells were grown in RPMI-1640 10%
FCS and detached by EDTA treatment (3 mM). A total of
5 x 10; cells were incubated on ice for 60-90 min in 500j1l of
FACS buffer (PBS with 0.1I% sodium azide and 1% BSA)
containing one of the following mouse monoclonal anti-
bodies at a concentration of 10-7 M: the anti-EGFR Ab
(Genzyme) or the anti-human TGF-a Ab (Ab-2. Oncogene
Science no. GFIO): MOPC21 served as non-specific control
antibody. After two cycles of washing (2 ml of FACS buffer)
followed by centrifugation (250g). biotinylated horse ant,-
mouse IgG Ab (Vector. Burlingame. CA. USA) was added
for 30 min (500p1 diluted 1:200). Cells were washed and
incubated with streptavidin-phycoerythrin (500 p1 diluted
1:50: Becton-Dickinson. San Jose. CA. USA) for 30 min.
After washing. cells were resuspended in 500 p1 of FACS
buffer and immediately analysed using a Becton Dickinson
FACScan. Dead cells were excluded by propidiumiodide
staining (I pLg ml l)
EGF and TGF-c quantification
To detect EGF and TGF-i in conditioned media. commer-
cial ELISA kits with a detection limit of 10 pg ml-' were
used (EGF quantitative ELISA Assay no. QIA02 and TGF-i
quantitative ELISA Assay no. QIA05. Oncogene Science.
Uniondale. NY. USA). Conditioned media were concentrat-
ed by dialysis against 0.1 mm sodium chloride (dialysis mem-
brane from Spectra Por. Houston, TX, USA; Mr cut-off:
1,000 daltons) at 4'C over 5 days followed by Speed-vac
evaporation. Dried samples were resuspended in sample
buffer in order to obtain up to 100-fold concentrated condi-
tioned media. The measurements were performed in duplicate
with at least two batches of supernatants for each cell line.
Membrane extraction and immunoblotting
Approximately 10' cells grown in RPMI-1640 10% FCS and
stored at - 70C were incubated for 40 mi in 36 ml of lysis
buffer (0.2 M HEPES. 1 mM EDTA, 0.1% BSA and I gM
leupeptin from Sigma). After homogenisation in a manual
glass homogeniser. a first centrifugation was performed at
1.000g for 15 min in order to remove large cell particles. The
supernatants were centrifuged for a second time at 50.000g
for 30 min. Pellets were resuspended in extraction buffer
(lysis buffer containing 35 mm octyl-p-D-thioglucoside from
Calbiochem. Behring Diagnostics. La Jolla. CA. USA) to a
final volume of 1.5 ml and stored at - 70°C. After thawing
and an additional centrifugation at 10.000g for 10min.
supernatant was applied by dotblotting on a nitrocellulose
membrane (0.2 pm. Schleicher & Schuell. Keene. NH. USA).
previously moistened with TBS (20 mM Tris-HCl. 1 M
sodium chloride pH 7.5). Blotted membrane extract was fixed
by a 30 min incubation in 1% glutaraldehyde in TBS. Non-
specific binding was reduced by treating the membranes for
1 h with 5% non-fat milk (Bio-Rad Laboratories. Hercules.
CA. USA) in TBS. Pro-TGF-a was detected using two anti-
bodies recognising different domains: a polyclonal sheep anti-
TGF-a Ab raised against mature human TGF-a (Biodesign.
Kennebunkport. ME. USA) and a rabbit polyclonal anti-pro-
TGFE- Ab directed against the intracellular domain of pro-
TGF-x (a gift from Dr Joan Massague). Antibodies were
diluted (1:1.000 for the sheep antibody and 1:5.000 for the
rabbit antibody) in antibody buffer (5% non-fat milk. 1%
gelatine. 0.5% Tween-20 in TBS). Membranes were incub-
ated in the antibody solution for 1 h. and thereafter washed
three times with antibody buffer. Affinity-purified donkey
anti-sheep antibody (diluted 1:5.000) or goat anti-rabbit
F(ab')2 fragment (diluted 1:3.000). both conjugated to
alkaline phosphatase (Jackson ImmunoResearch. Milan
Analytica. La Roche. Switzerland). were used as second
antibodies. After three wash steps with antibody buffer fol-
lowed by two wash steps with substrate buffer (4 mm
magnesium chloride. 0.1 m diethyl barbituric acid sodium
salt. from Fluka. Buchs. Switzerland). the substrate cocktail
[BCIP NBT alkaline phosphatase colour development solu-
tion, following the manufacturer's (BioRad) instructions] was
added for 45 min at 37°C.
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Fiue 1 Dose-response patterns of the cell lines ZL5. ZL34.
ZL55 and SPC212 to EGF (0) and TGF-a (0). The mitogenic
activity is defined as ['H]thymidine incorporation 24 h after treat-
ment of the cells with growth factor as compared with untreated
control. Points represent means of quadruplicates± s.d.852 I.A. MOROCZ et al.
Results
Mitogenic effect ofexogenous EGFand TGF--a
The effect of EGF and TGF-x on DNA synthesis was tested
on four human mesothelioma cell lines using a [HJthymidine
incorporation assay. In three of four cell nes, addition of
the growth factors resulted in an increase of [3H]thymidine
incorporation, as measured 24 h after treatment of serum-
depleted cells. The responsiveness varied from cell line to cell
lne (Figure 1). ZL5 and SPC212 cells were highly sensitive
6
EGFR
and showed typical dose-response patterns with both growth
factors. ZL55 cells were less sensitive; nevertheless, a
significant stimulatory effect (P < 0.01) was obtained in the
presence of lOngml-' TGF-z or EGF. In contrast, there
was no increase in [3Hlthymidine incorporation of ZL34 cells
in the presence of EGF or TGF-(.
Expression ofEGFR on the cell surface
The presence of EGFR was examined on the four mesothe-
lioma cell lines and on two control cell lines, including the
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FeLg 2 Flow cytometric analysis of EGFR expression on four mesothelioma cell lines and on the two cell lines NCI-H69 and
A431 as a neative and positive control respectively. The reative fluorescence is measured after indirct immunofluorescence
staning with anti-EGFR monoclonal antibody. The peaks at the left side (control) represent the background staining obtained with
the biotinylated second antibody and streptavidin-phycoerythrin alone.
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human small-cell lung cancer cell line NCI-H69 as an EGFR-
negative control (Weynants et al., 1990) and the human vulva
epidermoid carcinoma cell lines, A431, characterised by
EGFR overexpression (Kawamoto et al., 1983), as a positive
control. Flow cytometric analysis, using a monoclonal anti-
EGFR antibody, revealed that all four mesothelioma cell
lines highly expressed EGFR on their surface (Figure 2). A
striking observation was that the cell line ZL34, which was
non-responsive to EGF and TGF-a, expressed the largest
amount of EGFR among the mesothelioma cell lines,
although not quite reaching the level of A431 cells.
Detection ofEGF and TGF-L in conditioned media
Conditioned media of the four mesothelioma cell lines were
concentrated 100-fold and tested for the presence of EGF
and TGF-( using commercially available ELISA kits. No
EGF could be detected in any supernatant. TGF-a, however,
was present in two of four conditioned media. The super-
natant of ZL34 cells contained TGF-x at a concentration of
7-15pgml[', corresponding to about 10-20pg of TGF-x
released per 106 cells. Unquantifiable trace amounts were
detected in the supernatant of ZL5 cells. Interestingly, these
two cell lines had previously been observed to grow in the
absence of serum, as they proliferated in RPMI-1640 medium
supplemented only with 0.05% BSA (unpublished observa-
tions). The two other cell lines, ZL55 and SPC212, which did
not release TGF-a, required serum for growth.
Flow cytometric analysis ofmembrane-boundpro-TGF-x
Mature soluble TGF-a is known to be cleaved from a
membrane-bound precursor. The four mesothelioma cell lines
were analysed by flow cytometry for the presence of un-
cleaved membrane-anchored pro-TGF-a using the anti-TGF-x
antibody Ab-2. Only the two TGF-x-releasing cell lines, ZL5
and ZL34, expressed the pro form (Figure 3). The signal was
more pronounced on ZL34 cells than on ZL5 cells. No
pro-TGF-a was detected on the cell lines ZL55 and SPC212
(data not shown), as could be suspected since no TGF-x was
found in their conditioned media. Since only the two meso-
thelioma cell lines, ZL5 and ZL34, which did not require
serum for growth, expressed TGF-x pro form and were able
to release mature TGF-a, we focused on these two cell lines
for further experiments.
Dot blot ofmembrane-boundpro-TGF-a
The presence of membrane-bound pro-TGF-a has been con-
firmed by dot blots of cell membrane extracts. Pro-TGF-a
was identified using two different antibodies recognising the
extracellular and the intracellular domains. Both antibodies
detected higher amounts of pro-TGF-x in membrane extract
of ZL34 cells than in the membrane extract of ZL5 cells
(Figure 4). As expected, commercial TGF-x used as control
was only recognised by the antibody directed against the
mature growth factor, and not by the antibody raised against
the cytoplasmic tail of membrane bound TGF-x.
Effect ofneutrahsing antibodies on DNA synthesis
To demonstrate the presence of an autocrine loop involving
TGF-a in the cell lines ZL5 and ZL34, we tested the ability
of neutralising antibodies directed against the ligand TGF-x
and its receptor EGFR to disrupt this loop. In the case of
ZL5 cells neither the anti-TGF-a antibody nor the anti-
EGFR antibody affected the DNA synthesis, as measured by
[3Hjthymidine incorporation (Figure 5a). However, a signi-
ficant (P<0.01) decrease in [3H]thymidine incorporation was
obtained in the cell line ZL34 in the presence of both neu-
tralising antibodies as compared with the non-specific control
antibody MOPC21 (Figure Sb). The treatment of the cells
with non-neutralising monoclonal anti-EGFR or with poly-
clonal anti-pro-TGF-a control antibodies gave similar results
as with MOPC21 antibody (data not shown).
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Fagwe 3 Flow cytometric analysis of membrane pro-TGF-a on
the mesotbelioma cell lines ZL5 and ZL34. The relative fluo-
rescence is measured after indirect immunofluorescence staining
with anti-TGF-a monoclonal antibody. The peaks at the left side
(control) represent the background staining obtained with the
biotinylated second antibody and streptavidin-phycoerythrin
alone.
The potential autocrine role of the EGF/TGF-x-EGFR
mitogenic pathway in human lung mesothelioma has been
investigated. Well-characterised cell lines were studied regard-
ing their responsiveness to exogenous EGF and TGF-x and
coexpression of these growth factors and EGFR. The respon-
siveness to exogenous EGF and TGF-a was highly hetero-
geneous. A striking observation was that the two cell lines
which proliferated in the absence of serum, ZL5 and ZL34,
strongly differed in their responsiveness to exogenous growth
factors. While ZL5 cells were highly responsive to exogenous
EGF and TGF-z, ZL34 cells completely failed to be stimu-
lated by these growth factors. Nevertheless, all cell lines,
including the non-responsive cell line ZL34, expressed equally
large amounts of EGFR. It would not have been surprising
to detect a lack of EGFR in the non-responding cell line
since it is known that in 20-50% of histological mesothe-
lioma samples no EGFR is detected (Darn et al., 1990;
Kayser et al., 1990; Ramael et al., 1991). We cannot exclude
the possibility that during establishment of the cell lines
selection of the EGFR-bearing tumour samples occurred,
since it has been reported that the presence of EGF in the
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Figure 4 Dot blot of membrane extracts of the cell lines ZL5
and ZL34 revealed with two distinct antibodies to TGF-a. A
20ml volume of membrane extract corresponding to 1.3 x 106
cells was applied on the nitrocellulose filter in the top slot; in
further slots, samples were serially diluted 1:5. a, The extracel-
lular domain of membrane-anchored TGF-a was detected using
the polyclonal anti-TGF-a antibody directed against the mature
form of TGF-a. b. Pro-TGF-a was revealed using the polyclonal
anti-pro-TGF-a antibody recognising the intracellular domain of
pro-TGF-x. Commercial mature TGF-a at different concentra-
tions served as control in a and b.
culture medium enhances the success rate in establishing
mesothelioma cell lines (Versnel et al.. 1989).
It has been demonstrated that mutated non-cleavable
forms of pro-TGF-a accumulating on transfected cells retain
their ability to interact with EGFR of neighbouring cells in
culture (Brachmann et al.. 1989: Anklesaria et al.. 1990). The
hypothesis that membrane-anchored TGF-a activates EGFR
of adjacent cells through a juxtacnrne mechanism has been
further supported by the observation that unmodified cell-
associated TGF-a is able to stimulate autonomous growth
(Zorbas & Yeoman. 1993). Directed secretion has been des-
cnrbed as another possibility to initiate signal transduction: in
this concept. TGF-a is released locally into the intercellular
space lying between two neighbouring cells which are in close
contact (Singer. 1992). Moreover, it has been postulated that
TGF-a interacts with EGFR intracellularly and induces cell
proliferation via an internal autocrine loop (Sizeland &
Burgess. 1992). It cannot be excluded that more than one
mode of ligand-receptor interaction is involved in a given
system.
Here we show that the two mesothelioma cell lines ZL5
and ZL34 release soluble TGF-a and express membrane-
anchored pro-TGF-a. In the cell line ZL5. an external auto-
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Fgwe 5 Effect of the neutralising anti-EGFR (A) and anti-
TGF-a (-) antibodies on [3H]thymidine incorporation in the cell
lines ZL5 and ZL34, in comparison to the non-specific antibody
MOPC21 (0). Points represents means of quadruplicates±s.d.
cnne loop involving TGF-a could not be demonstrated, since
neutralising antibodies directed against TGF-a or EGFR had
no effect on DNA synthesis. Whether the inability of neutral-
ising antibodies to block proliferation is due to the existence
of an internal loop or/and directed secretion of TGF-x and,
or an unrelated mechanism is not yet clearly elucidated.
Interestingly, ZL5 cells were highly responsive to a whole
panel of conditioned media and exogenous growth factors
(Lauber et al., 1993). including EGF and TGF-a. Our pre-
vious results indicate that a partially characterised ZL5-
derived growth activity (MGA: mesothelioma-derived growth
activity) is not related to EGF-like molecules (Lauber et al.,
1993; Schmitter et al., 1993). We conclude that, although a
potential autocrine role of TGF-a cannot be excluded, there
is at least one other mechanism involved in the autocrine-
regulated growth of the cell line ZL5.
In the case of the cell line ZL34, neutralising antibodies
directed against TGF-( or EGFR inhibited DNA synthesis,
pointing to the existence of an external autocrine TGF-a
loop. DNA synthesis was only partially reduced after treat-
ment with neutralising antibodies. The residual DNA syn-
thesis could be due to EGFR activation in compartments
which are not accessible to antibodies (internal autocrine
loop or directed secretion) and, or to an unrelated mechan-
ism, as in ZL5 cells. Indeed, ZL34 cells also produce a
mitogenic activity with similar characteristics as the ZL5-
derived growth activity (MGA) (our own results).
In vitro studies with normal human mesothelial cells have
shown that transfection with the activated c-H-ras oncogene
EJ-ras leads to EGF independency and release of an uniden-
tified EGF-like activity (Tubo & Rheinwald, 1987). It could
well be that the EGF-like substance secreted by these ras-
transformed mesothelial cells was identical to TGF-x, as has
been reported in the case of similarly treated mouse mam-
mary cells (Salomon et al., 1987). A correlation between the
expression of ras and the amount of released TGF-a hasTGF-a/EGFR MITOGENIC PATHWAY IN MESOTHELIOMA 855
been reported in transfected rat intestinal epithelial cells (Fil-
mus et al., 1993). Furthermore, the human mesothelial cell
line MeT5A, immortalised by SV40 transfection, became
tumorigenic after transformation with EJ-ras (Reddel et al.,
1989). Taken together, these observations suggest that in the
case of the human mesothelioma cell lines ZL34 the produc-
tion of TGF-a might be linked to ras oncogene activation,
although K-ras activation has so far not been detected in
mesothelioma cell lines (Metcalf et al., 1992).
Exposure to asbestos fibres produces various immuno-
logical reactions in the mammalian lung. In rats chrysotile
asbestos fibres stimulate the alveolar macrophages to release
tumour necrosis factor a (TNF-a) and other inflammatory
mediators (Dubois et al., 1989; Ouellet et al., 1993). Human
monocytes in vitro exposed to asbestos release TNF-a among
other cytokines in a dose-dependent manner (Prewitt et al.,
1993). It has been shown that exogenous TNF-a up-regulates
in vitro expression ofTNF-a and EGFR in human pancreatic
carcinoma cells (Schmiegel et al., 1993). Interestingly, ZL34
cells produce TNF-a (our own observation) as well as granu-
locyte-macrophage colony-stimulating factor (GM-CSF)
(Schmitter et al., 1992), which is known as an activator of
TNF-a production (Lindemann et al., 1988). Moreover ZL34
cells secrete interferon-y (our own observation), a cytokine
which also enhances TGF-a expression (Hamburger & Pinna-
maneni, 1993). Thus, ZL34 cells release various cytokines
potentially involved in the up-regulation of TGF-a, which
might be an additional indication for the significant role of
TGF-a in ZL34 cells.
To date several possibilities of loss of growth control in
mesothelioma have been described:
1. Platelet-denrved growth factor (PDGF) has been postulat-
ed to act as an autocrine growth factor in mesothelioma
(Gerwin et al., 1987). While initially it remained unclear
whether PDGF-A or -B chain might be involved (Versnel
et al.. 1988, 1991; Langerak et al., 1993), recent reports
favour the hypothesis of an involvement of PDGF-A
chain, since in vitro treatment with antisense oligo-
nucleotides to the PDGF-A gene, but not to the PDGF-B
gene, result in a significant inhibition of mesothelioma cell
growth (Garlepp et al., 1993). Furthermore, the SV40
immortalised mesothelial cell line MeT5A transfected with
the PDGF-A gene becomes tumorigenic (Van der Meeren
et al., 1993).
2. A specific cytoplasmic S200 protein with an autocrine
mitogenic activity for mesothelial and mesothelioma cells
has been described by Donna et al. (1992).
3. We have previously reported the presence of an external
autocrine loop involving an unidentified mitogen in the
cell line ZL5 (Lauber et al., 1992, 1993).
4. In this report, we now describe an autocrine loop involv-
ing TGF-a/EGFR in the mesothelioma cell line ZL34.
This diversity of mechanisms affecting growth regulation
might reflect carcinogenesis ofmesothelioma as a result of
exposure to carcinogenic fibres. A multitude of alterations
including oncogene activations and immunological effects
as well as diverse chromosomal rearrangements and DNA
damages (Lechner et al., 1985; Barrett et al., 1989) have
been reported. Therefore, although the initial cause of
mesothelioma is known, a lot more information needs to
be obtained to determine whether there exists a common
tumorigenic alteration in mesothelioma which could help
in understanding mesothelial carcinogenesis and, ulti-
mately, serve as a starting point for successful therapy.
Abbevio BSA, bovine serum albumin; EGF, epidemal growth
factor, EGFR, epidermal growth factor receptor, ELISA, enzyme-
linked immunosorbent assay; FCS, fetal calfserum; PBS, phosphate-
buffered sahne; TGF-a, transforming growth factor a.
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